Comparing the current results to its competitors, Kiniksa Pharmaceuticals International Plc reported Revenue increase in the 1 quarter 2026 by 55.51 % year on year. The sales growth was above Kiniksa Pharmaceuticals International Plc's competitors' average revenue growth of 11.67 %, achieved in the same quarter.
Kiniksa Pharmaceuticals International Plc Net Income in the 1 quarter 2026 grew year on year by 164.57%, while most of its competitors have experienced a contraction in net income by -30.46 %.
Kiniksa Pharmaceuticals International Plc's Comment on Competition and Industry Peers
The company operates in the biotechnology and pharmaceutical industry, which is characterized by rapid technological advances and a focus on proprietary products. It faces competition from pharmaceutical and biotechnology companies, academic institutions, governmental agencies, and public and private research institutions. The company is aware of drugs currently marketed or in clinical development for the diseases it targets or plans to target. Regarding ARCALYST for recurrent pericarditis, the company is not aware of any other FDA-approved therapies but recognizes several competitors developing treatments. Competition may impact the company's ability to market and commercialize its products and product candidates.
Due to outstanding performance in Overall company, revenue grew by 55.51 % Kiniksa Pharmaceuticals International Plc improved its market share, to approximately 0.15 %.
October 17, 2025
Kiniksa Pharmaceuticals Receives U.S. FDA Orphan Drug Designation for KPL-387 in Pericarditis Treatment LONDON, Oct. 17, 2025 Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA), a biopharmaceutical company focused on developing and commercializing novel therapies for diseases with unmet needs, particularly in the cardiovascular space, has announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to KPL-387. This designation pertains to the treatment of pericarditis, including its recurrent form.KPL-387 is an independently developed monoclonal antibody that targets the human interleukin-1 receptor 1 (IL-1R1). By inhibiting the signaling activity of the cytokines i...
January 4, 2024
Kiniksa Pharmaceuticals has announced yet another remarkable milestone in its Q4 financial report. A key highlight of this announcement is the firm s impressive growth surge for its product ARCALYST (rilonacept), which witnessed an approximately 90% leap in net product revenue year-over-year to a staggering $233.1 million, a figure that remains unaudited.ARCALYST, a well-known product of Kiniksa Pharmaceuticals, is a dimeric fusion protein used for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and Muckle-Wells syndrome. A substantial rise in the revenue generated from this product has proven to be a significant windfall for the Pharmaceutical gia...
Publicly Traded Peers of Kiniksa Pharmaceuticals International Plc
Vertex Pharmaceuticals Inc Share Performance
+40.57%
One Year
Vertex Pharmaceuticals Inc
Profile
Vertex Pharmaceuticals Incs business model centers on the research and development of innovative therapies, primarily targeting cystic fibrosis and other serious diseases. They emphasize collaboration with organizations, strategic partnerships, and robust investment in R&D to deliver transformative treatments to patients and enhance their quality of life.
Biovie Inc is a biotechnology company that aims to develop advanced therapeutic solutions for various diseases. They have a unique business model that focuses on research and development of innovative drugs, strategic partnerships and collaborations with other organizations, along with potential commercialization of their products to generate revenue. Their goal is to create groundbreaking medical treatments that improve the quality of life for patients.
Bristol Myers Squibb Company operates a research and development-driven business model, focusing on the discovery and delivery of innovative medicines for various diseases. It emphasizes collaboration with academic institutions, government entities, and other pharmaceutical firms to enhance its therapeutic portfolio and improve patient outcomes.
Calcimedica Inc is a biopharmaceutical company that focuses on the research and development of small molecule drugs to treat a range of diseases caused by calcium dysregulation. Their business model involves identifying potential drug candidates, conducting preclinical and clinical trials, and eventually commercializing these drugs to address unmet medical needs.
Cellectar Biosciences Inc is a biopharmaceutical company that focuses on the development of targeted cancer therapies. They utilize their proprietary drug conjugation platform to create targeted small molecules that can selectively bind and deliver radioactive isotopes directly to cancer cells. Their business model revolves around developing and commercializing these innovative therapies for the treatment of various types of cancer, aiming to improve patient outcomes and potentially revolutionize cancer treatment.
Sources:
Kiniksa Pharmaceuticals International Plc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Kiniksa Pharmaceuticals International Plc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
